Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Barrett Esophagus 13Esophageal Neoplasms 7Rectal Neoplasms 6Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 6Nasopharyngeal Carcinoma 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Polyps 3Lung Neoplasms 3Precancerous Conditions 2Pathologic Complete Response 2Hyperplasia 2Gastroesophageal Reflux 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adenomatous Polyposis Coli 2Adenocarcinoma 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Recurrence 1Polyposis, Gastric 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Metaplasia 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21Standard of Care 20Sirolimus 20Azacitidine 20venetoclax 19Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × Endoscopy × Clear all
NCT05660421 2026-04-27

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Withdrawn
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡